Regenxbio Inc (RGNX)
32.24
+0.69 +2.19%
NASDAQ
Aug 5, 16:58
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 155.81M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -3.12 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -121.35M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 74.31% |
| Profit Margin (Quarterly) | -265.5% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0% |
| Price and Valuation | |
| Market Cap | 1.371B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 8.038 |
| PE Ratio | -- |
| Price to Book Value | 2.472 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow (Quarterly) | -72.15M |
| Return on Equity | Upgrade |
View All RGNX News
News
-
WireHeadlineTime (ET)
-
PR Newswire08/02 16:05
-
Yahoo07/29 15:05
-
Yahoo07/20 08:36
-
MT Newswires07/16 14:27
-
SA Breaking News07/16 12:56
-
PR Newswire06/09 07:05
-
Yahoo05/14 14:52
-
Yahoo05/14 14:40
-
SA Breaking News05/14 07:38
-
PR Newswire05/14 07:05
-
SA Breaking News05/07 15:30
-
MT Newswires05/07 10:29
-
PR Newswire05/06 16:05
-
Yahoo05/06 00:31
-
Yahoo05/05 19:15
-
MT Newswires05/05 16:30
-
MT Newswires05/05 16:30
-
PR Newswire05/05 16:05
-
PR Newswire04/28 16:05
-
PR Newswire04/27 16:55
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 08/09/2021 | Earnings Results | Q2 2021 Earnings Results |
| 08/09/2021 16:30 EST | Earnings Calls | Q2 2021 Earnings Call |
| 06/04/2021 09:00 EST | AGM | 2021 Annual General Meeting |
| 05/05/2021 | Earnings Results | Q1 2021 Earnings Results |
| 05/05/2021 16:30 EST | Earnings Calls | Q1 2021 Earnings Call |
| 03/01/2021 | Earnings Results | Q4 2020 Earnings Results |
| 03/01/2021 16:30 EST | Earnings Calls | Q4 2020 Earnings Call |
| 11/04/2020 | Earnings Results | Q3 2020 Earnings Results |
| 11/04/2020 16:30 EST | Earnings Calls | Q3 2020 Earnings Call |
| 08/06/2020 16:30 EST | Earnings Calls | Q2 2020 Earnings Call |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).
- URL: https://www.regenxbio.com
- Investor Relations URL: http://ir.regenxbio.com/
- HQ State/Province: Maryland
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Blend
- Next Earnings Release: Aug. 09, 2021
- Last Earnings Release: May. 05, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 32.24 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| SMHCKX | ST Healthcare Innovations 11 RE | 3.63% |
| PBE | Invesco Dynamic Biotech & Genome ETF | 2.66% |
| F00001553Q | AAM Biotechnology Opps 2020-1 CA | 1.70% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- RGNX Tweets Stocktwits
Advertisement
